ASH News Daily - Monday, December 12, 2011 - (Page A-15)

Monday, December 12, 2011 LYMPHOMA QUALITY Spotlight on Lymphoma: The Latest on Biology And Biologic Treatments The Importance of Quality Indicators — By aManda Brandow, do, MS By BarBara pro, Md I treatment of lymphoma. In Room 5AB, San Diego Convention Center, from 7:30 to 9:00 a.m., there will be an oral session (abstracts 949-954) which will focus on how biologic determinants affect the outcome of diffuse large B-cell lymphoma (DL- A What You Need to Know Now Center. In particular, presenters will discuss how quality indicator measures are derived, how they can be measured, the potential consequences of failure to adhere to these indicators, and the challenges that quality indicators pose to particular hematologic populations. Dr. Richard Lottenberg, Univer- This afternoon, attendees will have the opportunity to learn about the importance of quality indicators at the ASH special symposium, “Quality Indicators: Examples of Relevance to Hematology” that will be held from 2:00 to 3:30 p.m. in Room 30 of the San Diego Convention f you are a lymphomaniac, be early and bright tomorrow morning to learn the latest on biology and re established quality indicators of sufficient quality for individual populations? BCL). Highlights will include the emerging role of t(14;18) as negative prognostic indicator in patients with DLBCL and germinal center B-cell subtype, the impact of the immune microenvironment on the outcome of patients of DLBCL, and the revisited role of our cheap but loyal friend immunohistochemistry. Information obtained from these studies will hopefully enable us to stratify patients for more specific therapies. sity of Florida, Gainesville, will discuss the challenges in defining the quality of health care for patients with sickle cell disease (SCD). Spe- session will be held in Room 6B, San Diego Convention Center, from 7:30 to 9:00 a.m., and will focus on new emerging therapies for nonHodgkin and Hodgkin lymphomas (abstracts 955-960). Dr. James Rubenstein will present the latest on safety and efficacy of intraventricular rituximab for patients with recurrent CNS lymphoma when used in two different doses and in combi- cifically, Dr. Lottenberg will discuss how the small number of randomized, controlled trials in SCD poses challenges for the development of quality indicators. In addition, he will present recent developments relevant to the establishment of quality indicators in SCD and the benefits of having well-defined quality indicators in SCD. Dr. Lottenberg will highlight how operationalizing quality indicators in SCD is a work in progress, since there are real chal- The second Simultaneous Oral An innovative approach to improving outcomes in patients with cancer This could allow potent Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 drugs to be delivered directly to tumor cells with minimal systemic toxicity. Optimizing the parameters for clinical success Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8 and potent cytotoxic agents.4,7,8 Elements of an antibody-drug conjugate Linker Antibody specific for a tumor-associated antigen that has restricted expression on normal cells4,8 Antibody specific for a tumor-associated antigen that has restricted expression on normal cells4,8 Cytotoxic agent kills target cells when internalized and released4,8 Cytotoxic agent kills target cells when internalized and released4,8 attaches the cytotoxic agent to the antibody. Newer linker systems are designed to be systemically stable and release the cytotoxic agent in targeted cancer cells4,8,9 attaches the cytotoxic agent to the antibody. Newer linker systems are designed to be systemically stable and release the cytotoxic agent in targeted cancer cells4,8,9 Linker ADCs link precision and potency for greater activity A preclinical (in vivo) study demonstrated that the ADC is more active than the antibody alone (mAb) or the admixture (mAb + cytotoxic agent unlinked)10 A preclinical (in vivo) study demonstrated that the ADC is more active than the antibody alone (mAb) or the admixture (mAb + cytotoxic agent unlinked)10 Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 drugs to be delivered directly to tumor cells with minimal systemic toxicity. This could allow potent nation with methotrexate. Dr. Anas Younes will present preliminary results of the combination of brentuximab vedotin, an anti-CD30 immunoconjugate, with ABVD or AVD in the treatment of patients with newly diagnosed advanced-stage Hodgkin lymphoma. Data on maximum tolerated dose and safety profile will be presented. But there is much more. Can we use antibiotics and doublearmed T-lymphocytes to treat aggressive lymphomas? Helicobacter pylori (Hp) is detected in about a third of patients with primary gastric diffuse large B-cell lymphoma, and the incidence is even higher in patients with concomitant mucosaassociated lymphoid tissue (MALT) lymphoma. While the role of Hperadicating therapy is well established in MALT lymphoma, the efficacy of this approach is not known in patients with DLBCL. Dr. Silvia Govi will present the results of a multicenter phase II trial suggesting that antibiotic therapy can be used as the sole treatment modality even in patients with an aggressive histology. One more etiologic agent associated with a number of lymphoproliferative disorders, is Epstein Barr virus (EBV). Dr. Catherine Bollard will show how immunotherapy with cytotoxic T-lymphocytes targeting EBV antigens is not only feasible but can induce responses in patients with EBV-positive lymphomas. Tweets from #ASH11 Chewing on great career development advice at #ASH11 Simultaneously exciting and ulcer-inducing... – prknlot At Successes in Bone Marrow Failures Symposium. Good session at #ASH11 – marrow Excited to hear updates from my colleagues attending @ ASH_hematology annual meeting. #ASH11 – hayeslat Loving 68 degree weather and palm trees in San diego. #ASH11 – alantanmd Science editor en route to #ASH11. If the crew needs to ask “is there a doctor on the plane?” they will be all SET. – BioWorld Kind of geeking out that #ASH11 has its own iPhone app! – deepfriedlard Dr. Pro receives research funding from Seattle Genetics and is a coauthor of one of the papers mentioned above. The future of drug treatment in cancer Seattle Genetics is dedicated to improving the lives of people with cancer by developing innovative therapies for hematologic malignancies and solid tumors. Go to seattlegenetics.com for your complimentary, comprehensive, 15-slide educational presentation. Just click on the download icon to get the slides delivered to your personal computer or mobile device. Go to seattlegenetics.com for your complimentary, comprehensive, 15-slide educational presentation. Just click on the download icon to get the slides delivered to your personal computer or mobile device. Seattle Genetics is dedicated to improving the lives of people with cancer by developing innovative therapies for hematologic malignancies and solid tumors. Download ADC scientific slide deck > Download ADC scientific slide deck > TRIM «« From Page A-14 Just landed for #ASH11 and there is a guy in just boxers at the baggage claim... – derekwimmer just teach, but really ‘trade education’ with our international African colleagues about hematologic diseases,” Dr. Lund said about his experiences. Next, Dr. Heather Ann Hume, Here in #ASH11 waiting T-cell lymphoma session. San Diego CA – humbertosinco Leadership in antibody-drug conjugate development www.seattlegenetics.comwww.seattlegenetics.com REFERENCES: 1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5-13. 2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146. 3. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659-687. 4. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-169. 5. Alley SC, Benjamin DR, Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-765. 6. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. 7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529-537. 8. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235-244. 9. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non–Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6): 2358-2364. 10. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784. © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved. Seattle Genetics andSeattle Genetics and Printed in USA © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved. are US registered trademarks of Seattle Genetics, Inc. US/ADC/2011/0030 US/ADC/2011/0030 are US registered trademarks of Seattle Genetics, Inc. Printed in USA REFERENCES: 1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5-13. 2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146. 3. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659-687. 4. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-169. 5. Alley SC, Benjamin DR, Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-765. 6. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. 7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529-537. 8. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235-244. 9. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non–Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6): 2358-2364. 10. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784. CHU Sainte-Justine, University of Montreal, Montreal, Canada, discussed the unique challenges in hospital transfusion practices encountered in Uganda’s largest referral hospital. Dr. Jean-Pierre Allain, University of Cambridge, United Kingdom, ended the session by reviewing national blood services in Sub-Saharan Africa, discussing the issues surrounding chronic blood shortages and the lack of a stable health service infrastructure to ensure the safety of the blood supply. Just got back from #ASH11 registration. Loved the monitor for the Twitter Feed. Are you following @ASH_hematology? Lisa_Palacios – Headed out to San Diego for #ASH11. – jghoggatt Drs. Garcia and Ghanny indicated no relevant conflicts of interest. Join the annual meeting conversation on Twitter. Use #ASH11 in your tweets from the meeting. Follow ASH on Twitter (@ash_hematology) for Society news, meeting information, advocacy updates, and much more. 10/25/11 2:37 PM10/25/11 2:37 PM lenges to providing SCD care even when there is strong evidence for improved outcomes. Dr. Lottenberg will also discuss the need to be aware of unintended consequences when developing quality indicators for SCD. “There needs to be validation of outcome measures. We need to assure quality indicators serve to enhance the capabilities of providers, rather »» QUALITY Page A-18 Saturday, December 10, 2011 ASH NEWS DAILYAIL Page A–15 ® ®

Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011

ASH News Daily - Monday, December 12, 2011

https://www.nxtbookmedia.com